Medicilon grants collaboration award to Revolution Medicines
Contract research organization Medicilon has presented its customer collaboration award to Revolution Medicines following a site visit to its Nanhui research facility.
Medicilon, a preclinical contract research organization, has officially recognized Revolution Medicines for its collaborative efforts in drug development. The award was presented during a visit by Revolution Medicines executives, including Dr. Yang Liu, Director of Medicinal Chemistry, and Senior Scientist Dr. Kristof Pota, to Medicilon’s research and development center in Nanhui.
The recognition highlights the ongoing partnership between the two firms, which centers on accelerating preclinical discovery processes. By aligning their technical teams, the companies aim to streamline early-stage pharmaceutical research through outsourced laboratory services.
This award acknowledges the transactional and technical synergy between the service provider and the biotechnology company. Such partnerships remain a common strategy in the pharmaceutical sector, as biotech firms increasingly rely on external CRO expertise to manage resource-heavy research pipelines and meet development timelines.